Zheng H, Xu Q, Ji D, Yang B, Ji X
Nat Commun. 2025; 16(1):2161.
PMID: 40038320
PMC: 11880454.
DOI: 10.1038/s41467-025-57513-2.
Duster R, Anand K, Binder S, Schmitz M, Gatterdam K, Fisher R
Nat Commun. 2024; 15(1):6597.
PMID: 39097586
PMC: 11297931.
DOI: 10.1038/s41467-024-50891-z.
Gong Y, Li H
Cell Commun Signal. 2024; 22(1):226.
PMID: 38605321
PMC: 11010440.
DOI: 10.1186/s12964-024-01577-y.
Duster R, Anand K, Binder S, Schmitz M, Gatterdam K, Fisher R
bioRxiv. 2024; .
PMID: 38405971
PMC: 10888979.
DOI: 10.1101/2024.02.14.580246.
Song X, Fang C, Dai Y, Sun Y, Qiu C, Lin X
Br J Cancer. 2024; 130(8):1239-1248.
PMID: 38355840
PMC: 11014910.
DOI: 10.1038/s41416-024-02589-8.
Unveiling the noncanonical activation mechanism of CDKs: insights from recent structural studies.
Li T, Tang H, Tsai K
Front Mol Biosci. 2023; 10:1290631.
PMID: 38028546
PMC: 10666765.
DOI: 10.3389/fmolb.2023.1290631.
CDK11 facilitates centromeric transcription to maintain centromeric cohesion during mitosis.
Zhang Q, Chen Y, Teng Z, Lin Z, Liu H
Mol Biol Cell. 2023; 35(2):ar18.
PMID: 38019613
PMC: 10881149.
DOI: 10.1091/mbc.E23-08-0303.
A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors.
Garralda E, Schram A, Bedard P, Schwartz G, Yuen E, McNeely S
Oncologist. 2023; 29(1):e131-e140.
PMID: 37531083
PMC: 10769797.
DOI: 10.1093/oncolo/oyad215.
Novel benzylidene benzofuranone analogues as potential anticancer agents: design, synthesis and in vitro evaluation based on CDK2 inhibition assays.
Pai A, B S J
3 Biotech. 2022; 12(10):256.
PMID: 36065423
PMC: 9440176.
DOI: 10.1007/s13205-022-03312-1.
Targeting transcription in heart failure via CDK7/12/13 inhibition.
Hsu A, Duan Q, Day D, Luo X, McMahon S, Huang Y
Nat Commun. 2022; 13(1):4345.
PMID: 35896549
PMC: 9329381.
DOI: 10.1038/s41467-022-31541-8.
Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions.
Juric V, Murphy B
Cancer Drug Resist. 2022; 3(1):48-62.
PMID: 35582046
PMC: 9094053.
DOI: 10.20517/cdr.2019.105.
Converged DNA Damage Response Renders Human Hepatocellular Carcinoma Sensitive to CDK7 Inhibition.
Xie G, Zhu A, Gu X
Cancers (Basel). 2022; 14(7).
PMID: 35406486
PMC: 8996977.
DOI: 10.3390/cancers14071714.
Transcriptional CDK Inhibitors as Potential Treatment Option for Testicular Germ Cell Tumors.
Funke K, Duster R, Wilson P, Arevalo L, Geyer M, Schorle H
Cancers (Basel). 2022; 14(7).
PMID: 35406461
PMC: 8997165.
DOI: 10.3390/cancers14071690.
Cryo-EM structure of TFIIH/Rad4-Rad23-Rad33 in damaged DNA opening in nucleotide excision repair.
van Eeuwen T, Shim Y, Kim H, Zhao T, Basu S, Garcia B
Nat Commun. 2021; 12(1):3338.
PMID: 34099686
PMC: 8184850.
DOI: 10.1038/s41467-021-23684-x.
Structure of TFIIK for phosphorylation of CTD of RNA polymerase II.
van Eeuwen T, Li T, Kim H, Gorbea Colon J, Parker M, Dunbrack R
Sci Adv. 2021; 7(15).
PMID: 33827808
PMC: 8026125.
DOI: 10.1126/sciadv.abd4420.
The cryoelectron microscopy structure of the human CDK-activating kinase.
Greber B, Perez-Bertoldi J, Lim K, Iavarone A, Toso D, Nogales E
Proc Natl Acad Sci U S A. 2020; 117(37):22849-22857.
PMID: 32855301
PMC: 7502720.
DOI: 10.1073/pnas.2009627117.
CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J, Zhang R, Lin Z, Zhang S, Chen Y, Tang J
J Hematol Oncol. 2020; 13(1):99.
PMID: 32690037
PMC: 7370470.
DOI: 10.1186/s13045-020-00926-x.
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.
Zhang H, Christensen C, Dries R, Oser M, Deng J, Diskin B
Cancer Cell. 2019; 37(1):37-54.e9.
PMID: 31883968
PMC: 7277075.
DOI: 10.1016/j.ccell.2019.11.003.
Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.
Shi C, Kuo K, Chen M, Chow P, Liu S, Chang Y
Cells. 2019; 8(11).
PMID: 31752390
PMC: 6912535.
DOI: 10.3390/cells8111469.
CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
Liu F, Jiang W, Sui Y, Meng W, Hou L, Li T
Proc Natl Acad Sci U S A. 2019; 116(26):12986-12995.
PMID: 31182587
PMC: 6600918.
DOI: 10.1073/pnas.1815780116.